Diamond Biotechnology Co., Ltd.(TW:6815)
NT$19.00-0.90 (-4.52%)
TW:6815
Diamond Biotechnology Co., Ltd. financials statements
NT$19.00
At close:-0.90 (-4.52%)
Diamond Biotechnology Co., Ltd. (6815) Ratios
Diamond Biotechnology Co., Ltd. Ratios
TW:6815's free cash flow for Q2 2026 was NT$63.93M. For the 2026 fiscal year, TW:6815's free cash flow was decreased by NT$-2.18M and operating cash flow was NT$66.11M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.28 | 3.28 | 1.50 | 1.22 | 1.77 |
| Quick Ratio | 2.67 | 2.73 | 1.20 | 0.97 | 1.38 |
| Cash Ratio | 0.96 | 0.74 | 0.30 | 0.33 | 0.25 |
| Solvency Ratio | -0.13 | 0.23 | 0.21 | 0.27 | 0.37 |
| Operating Cash Flow Ratio | -0.01 | 0.16 | 0.15 | 0.52 | 0.03 |
| Short-Term Operating Cash Flow Coverage | -0.04 | 1.24 | 0.25 | 0.94 | 0.06 |
| Net Current Asset Value | NT$ 172.43M | NT$ 256.13M | NT$ -55.08M | NT$ 41.45M | NT$ 87.66M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.27 | 0.24 | 0.44 | 0.34 | 0.33 |
| Debt-to-Equity Ratio | 0.43 | 0.40 | 1.02 | 0.71 | 0.66 |
| Debt-to-Capital Ratio | 0.30 | 0.29 | 0.50 | 0.42 | 0.40 |
| Long-Term Debt-to-Capital Ratio | 0.24 | 0.26 | 0.35 | 0.07 | 0.13 |
| Financial Leverage Ratio | 1.60 | 1.70 | 2.31 | 2.08 | 1.98 |
| Debt Service Coverage Ratio | -0.59 | 3.15 | 0.61 | 0.53 | 1.12 |
| Interest Coverage Ratio | -14.30 | 15.15 | 8.50 | 12.41 | 21.16 |
| Debt to Market Cap | 0.09 | 0.12 | 0.17 | 0.29 | 0.18 |
| Interest Debt Per Share | 6.05 | 8.26 | 11.56 | 7.86 | 6.55 |
| Net Debt to EBITDA | -1.91 | 0.73 | 2.36 | 1.18 | 1.14 |
| Profitability Margins | |||||
| Gross Profit Margin | 30.96% | 43.05% | 47.00% | 42.39% | 47.54% |
| EBIT Margin | -14.89% | 13.42% | 10.69% | 10.48% | 13.75% |
| EBITDA Margin | -9.16% | 17.07% | 18.86% | 22.78% | 28.52% |
| Operating Profit Margin | -14.79% | 14.68% | 10.37% | 10.67% | 12.17% |
| Pretax Profit Margin | -15.92% | 12.46% | 9.47% | 9.62% | 13.17% |
| Net Profit Margin | -14.02% | 9.53% | 7.59% | 7.68% | 10.61% |
| Continuous Operations Profit Margin | -14.02% | 9.53% | 7.59% | 7.68% | 10.61% |
| Net Income Per EBT | 88.06% | 76.50% | 80.13% | 79.83% | 80.54% |
| EBT Per EBIT | 107.62% | 84.87% | 91.27% | 90.12% | 108.23% |
| Return on Assets (ROA) | -8.09% | 6.93% | 5.85% | 5.30% | 7.75% |
| Return on Equity (ROE) | -12.98% | 11.75% | 13.49% | 11.03% | 15.35% |
| Return on Capital Employed (ROCE) | -10.36% | 13.32% | 11.99% | 14.13% | 14.14% |
| Return on Invested Capital (ROIC) | -8.42% | 9.85% | 7.31% | 7.15% | 8.55% |
| Return on Tangible Assets | -8.10% | 6.95% | 5.91% | 5.41% | 8.02% |
| Earnings Yield | -2.83% | 3.43% | 2.28% | 5.10% | 5.68% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.21 | 3.04 | 3.08 | 2.98 | 2.12 |
| Payables Turnover | 18.07 | 6.09 | 9.01 | 5.44 | 5.21 |
| Inventory Turnover | 3.77 | 3.79 | 4.17 | 3.28 | 2.64 |
| Fixed Asset Turnover | 1.44 | 2.20 | 1.64 | 2.36 | 3.01 |
| Asset Turnover | 0.58 | 0.73 | 0.77 | 0.69 | 0.73 |
| Working Capital Turnover Ratio | 1.21 | 2.52 | 6.20 | 3.92 | 2.94 |
| Cash Conversion Cycle | 163.37 | 156.48 | 165.35 | 166.74 | 240.11 |
| Days of Sales Outstanding | 86.73 | 119.96 | 118.33 | 122.55 | 171.86 |
| Days of Inventory Outstanding | 96.84 | 96.41 | 87.51 | 111.25 | 138.31 |
| Days of Payables Outstanding | 20.20 | 59.89 | 40.49 | 67.06 | 70.06 |
| Operating Cycle | 183.57 | 216.37 | 205.84 | 233.80 | 310.17 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.05 | 1.07 | 1.31 | 5.66 | 0.20 |
| Free Cash Flow Per Share | -0.08 | 0.11 | -5.00 | 3.04 | -0.69 |
| Dividend Paid and CapEx Coverage Ratio | -0.27 | 0.96 | 0.20 | 2.05 | 0.22 |
| Capital Expenditure Coverage Ratio | -1.84 | 1.12 | 0.21 | 2.16 | 0.23 |
| Operating Cash Flow Coverage Ratio | -0.01 | 0.13 | 0.12 | 0.73 | 0.03 |
| Operating Cash Flow to Sales Ratio | -0.00 | 0.04 | 0.07 | 0.36 | 0.01 |
| Free Cash Flow Yield | -0.13% | 0.16% | -7.60% | 12.92% | -2.61% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -35.39 | 35.85 | 51.76 | 19.61 | 17.58 |
| Price-to-Sales (P/S) Ratio | 4.96 | 2.78 | 3.32 | 1.51 | 1.87 |
| Price-to-Book (P/B) Ratio | 4.59 | 3.43 | 5.91 | 2.16 | 2.70 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -772.98 | 609.91 | -13.15 | 7.74 | -38.36 |
| Price-to-Operating Cash Flow Ratio | -1193.39 | 63.40 | 50.07 | 4.16 | 130.80 |
| Price-to-Earnings Growth (PEG) Ratio | 0.18 | 0.72 | 8.87 | -0.96 | 0.07 |
| Enterprise Value Multiple | -56.08 | 17.02 | 19.99 | 7.79 | 7.69 |
| Enterprise Value | 2.58B | 2.23B | 2.32B | 771.05M | 867.21M |
| EV to EBITDA | -56.08 | 17.02 | 19.99 | 7.79 | 7.69 |
| EV to Sales | 5.14 | 2.91 | 3.77 | 1.77 | 2.19 |
| EV to Free Cash Flow | -800.22 | 637.17 | -14.91 | 9.12 | -45.05 |
| EV to Operating Cash Flow | -1235.45 | 66.23 | 56.77 | 4.89 | 153.62 |
| Tangible Book Value Per Share | 13.69 | 19.75 | 10.87 | 10.42 | 9.16 |
| Shareholders’ Equity Per Share | 13.72 | 19.86 | 11.12 | 10.88 | 9.82 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.12 | 0.24 | 0.20 | 0.20 | 0.19 |
| Revenue Per Share | 12.70 | 24.49 | 19.77 | 15.63 | 14.21 |
| Net Income Per Share | -1.78 | 2.33 | 1.50 | 1.20 | 1.51 |
| Tax Burden | 0.88 | 0.76 | 0.80 | 0.80 | 0.81 |
| Interest Burden | 1.07 | 0.93 | 0.89 | 0.92 | 0.96 |
| Research & Development to Revenue | 0.09 | 0.05 | 0.05 | 0.06 | 0.07 |
| SG&A to Revenue | 0.36 | 0.23 | 0.26 | 0.17 | 0.28 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.03 | 0.35 | 0.88 | 4.72 | 0.13 |
Currency in TWD
